Refractory anemia with ring sideroblasts

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 4, 2013, Pages 377-385

  Malcovati, Luca ^a,b   Cazzola, Mario ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

myelodysplastic syndrome; myelodysplastic myeloproliferative neoplasm; ring sideroblast; RNA splicing; SF3B1

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRON; MUTANT PROTEIN; RECOMBINANT ERYTHROPOIETIN; SF3B1 PROTEIN; UNCLASSIFIED DRUG;

CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; MITOCHONDRION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; RISK ASSESSMENT; SOMATIC MUTATION; THROMBOCYTOSIS;

MYELODYSPLASTIC SYNDROME; MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM; RING SIDEROBLAST; RNA SPLICING; SF3B1;

ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; ERYTHROPOIESIS; FERRITINS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IRON; LEUKEMIA, MYELOID, ACUTE; MITOCHONDRIAL PROTEINS; MUTATION; MYELOID CELLS; PHOSPHOPROTEINS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; THROMBOCYTOSIS;

EID: 84893729468     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.09.005     Document Type: Review

References (53)

1. G.E. Cartwright, and A. Deiss Sideroblasts, siderocytes, and sideroblastic anemia N Engl J Med 292 1975 185 193
2. G.J. Mufti, J.M. Bennett, and J. Goasguen et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts Haematologica 93 2008 1712 1717
3. T. Alcindor, and K.R. Bridges Sideroblastic anaemias Br J Haematol 116 2002 733 743
4. S.E. Bjorkman Chronic refractory anemia with sideroblastic bone marrow; a study of four cases Blood 11 1956 250 259
5. J.M. Bennett, D. Catovsky, and M.T. Daniel et al. Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 1982 189 199
6. J.W. Vardiman, N.L. Harris, and R.D. Brunning The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 2002 2292 2302
7. S. Levi, B. Corsi, and M. Bosisio et al. A human mitochondrial ferritin encoded by an intronless gene J Biol Chem 276 2001 24437 24440
8. M. Cazzola, R. Invernizzi, and G. Bergamaschi et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia Blood 101 2003 1996 2000
9. P.D. Cotter, D.L. Rucknagel, and D.F. Bishop X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley Blood 84 1994 3915 3924
10. R. Allikmets, W.H. Raskind, and A. Hutchinson et al. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A) Hum Mol Genet 8 1999 743 749
11. D.L. Guernsey, H. Jiang, and D.R. Campagna et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia Nat Genet 41 2009 651 653
12. D.P. Steensma, K.A. Hecksel, and J.C. Porcher et al. Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts) Leuk Res 31 2007 623 628
13. N. Gattermann, M. Wulfert, and B. Junge et al. Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome Blood 103 2004 1499 1502
14. M.G. Shin, S. Kajigaya, and B.C. Levin et al. Mitochondrial DNA mutations in patients with myelodysplastic syndromes Blood 101 2003 3118 3125
15. A. Pellagatti, M. Cazzola, and A.A. Giagounidis et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype Blood 108 2006 337 345
16. M.G. Della Porta, L. Malcovati, and A. Gallì et al. Mitochondrial ferritin expression and clonality of hematopoiesis in patients with refractory anemia with ringed sideroblasts Blood 106 2005 3444
17. E. Papaemmanuil, M. Cazzola, and J. Boultwood et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts N Engl J Med 365 2011 1384 1395
18. L. Malcovati, E. Papaemmanuil, and D.T. Bowen et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms Blood 118 2011 6239 6246
19. K. Yoshida, M. Sanada, and Y. Shiraishi et al. Frequent pathway mutations of splicing machinery in myelodysplasia Nature 478 2011 64 69
20. M.M. Patnaik, T.L. Lasho, and J.M. Hodnefield et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value Blood 119 2012 569 572
21. F. Damm, O. Kosmider, and V. Gelsi-Boyer et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes Blood 119 2012 3211 3218
22. F. Thol, S. Kade, and C. Schlarmann et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes Blood 119 2012 3578 3584
23. J.W. Vardiman, J. Thiele, and D.A. Arber et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
24. M. Cazzola, M. Rossi, and L. Malcovati Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms Blood 121 2013 260 269
25. J. Boultwood, A. Pellagatti, and M. Nikpour et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts PLoS ONE 3 2008 e1970
26. M. Nikpour, C. Scharenberg, and A. Liu et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts Leukemia 27 2013 889 896
27. V. Visconte, H.J. Rogers, and J. Singh et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes Blood 120 2012 3173 3186
28. N. Gattermann, C. Aul, and W. Schneider Two types of acquired idiopathic sideroblastic anaemia (AISA) Br J Haematol 74 1990 45 52
29. L. Malcovati, M. Della Porta, and C. Pascutto et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria. A basis for clinical decision-making J Clin Oncol 23 2005 7594 7603
30. U. Germing, C. Strupp, and A. Kuendgen et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes Haematologica 91 2006 1596 1604
31. S.H. Swerdlow, E. Campo, and N.L. Harris et al. WHO classification of tumors of haematopoietic and lymphoid tissues 2008 IARC Lyon (France) 89 107
32. M. Cazzola, G. Barosi, and P.G. Gobbi et al. Natural history of idiopathic refractory sideroblastic anemia Blood 71 1988 305 312
33. I. Ambaglio, L. Malcovati, and E. Papaemmanuil et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 Haematologica 98 2013 420 423
34. P. Greenberg, C. Cox, and M.M. LeBeau et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088
35. P.L. Greenberg, H. Tuechler, and J. Schanz et al. Revised international prognostic scoring system for myelodysplastic syndromes Blood 120 2012 2454 2465
36. L. Malcovati, U. Germing, and A. Kuendgen et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 2007 3503 3510
37. E. Hellstrom-Lindberg, T. Ahlgren, and Y. Beguin et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients Blood 92 1998 68 75
38. N. Casadevall, P. Durieux, and S. Dubois et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial Blood 104 2004 321 327
39. P.L. Greenberg, Z. Sun, and K.B. Miller et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) Blood 114 2009 2393 2400
40. E. Hellstrom-Lindberg, R. Negrin, and R. Stein et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model Br J Haematol 99 1997 344 351
41. E. Hellstrom-Lindberg, N. Gulbrandsen, and G. Lindberg et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life Br J Haematol 120 2003 1037 1046
42. M. Cazzola, and L. Malcovati Myelodysplastic syndromes-coping with ineffective hematopoiesis N Engl J Med 352 2005 536 538
43. M.G. Della Porta, L. Malcovati, and C. Strupp et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome Haematologica 96 2011 441 449
44. M.G. Della Porta, L. Malcovati, and E. Travaglino et al. A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes ASH Annu Meet Abstr 110 2007 2453-
45. C.S. Cutler, S.J. Lee, and P. Greenberg et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 104 2004 579 585
46. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 2009 223 232
47. G.R. Shaw Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults Br J Haematol 131 2005 180 184
48. H. Szpurka, R. Tiu, and G. Murugesan et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation Blood 108 2006 2173 2181
49. L. Malcovati, M.G. Della Porta, and D. Pietra et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis Blood 114 2009 3538 3545
50. A.H. Schmitt-Graeff, S.S. Teo, and M. Olschewski et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis Haematologica 93 2008 34 40
51. S. Jeromin, T. Haferlach, and V. Grossmann et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms Haematologica 98 2013 e15 e17
52. H. Szpurka, L.P. Gondek, and S.R. Mohan et al. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation Leukemia 23 2009 610 614
53. J. Broseus, L. Florensa, and E. Zipperer et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis Haematologica 97 2012 1036 1041